Navigation Links
Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
Date:3/31/2008

ly dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE(R) which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and CETHRIN, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained he
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Raises $5 Million
2. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
3. Barr Pharmaceuticals, Inc. Executive Bios
4. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
5. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
6. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
7. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
8. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
9. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
10. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
11. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:SIRIUS Satellite Radio to Launch 'Doctor Radio,' a Groundbreaking, 24/7 Health and Wellness Channel, in Partnership With NYU Medical Center 2Health News:SIRIUS Satellite Radio to Launch 'Doctor Radio,' a Groundbreaking, 24/7 Health and Wellness Channel, in Partnership With NYU Medical Center 3Health News:SIRIUS Satellite Radio to Launch 'Doctor Radio,' a Groundbreaking, 24/7 Health and Wellness Channel, in Partnership With NYU Medical Center 4Health News:SIRIUS Satellite Radio to Launch 'Doctor Radio,' a Groundbreaking, 24/7 Health and Wellness Channel, in Partnership With NYU Medical Center 5Health News:Schlafender Hase Releases Text Verification Tool 4.0 2Health News:Family counseling improves lives of patients and spouses coping with prostate cancer 2Health News:Factor key to severity of community-associated methicillin-resistant staph infections identified 2Health News:Factor key to severity of community-associated methicillin-resistant staph infections identified 3Health News:New Test Criteria Spots Rheumatoid Arthritis Sooner 2Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 2Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 3Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 4Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 5Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 6
Breaking Medicine Technology:Negative Pressure Wound Devices Draw FDA Notice, Advice 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Pew Report Documents Challenges Faced by Philadelphia in Paying for City Workers Pensions and Health Care 50288 1Pew Report Documents Challenges Faced by Philadelphia in Paying for City Workers Pensions and Health Care 50288 2Pew Report Documents Challenges Faced by Philadelphia in Paying for City Workers Pensions and Health Care 50288 3Pew Report Documents Challenges Faced by Philadelphia in Paying for City Workers Pensions and Health Care 50288 4Pew Report Documents Challenges Faced by Philadelphia in Paying for City Workers Pensions and Health Care 50288 5Pew Report Documents Challenges Faced by Philadelphia in Paying for City Workers Pensions and Health Care 50288 6Surgeons Use USGI Medicals Incisionless Operating Platform to Reduce Pouch Stoma Size in Gastric Bypass Patients 50285 1Surgeons Use USGI Medicals Incisionless Operating Platform to Reduce Pouch Stoma Size in Gastric Bypass Patients 50285 2Surgeons Use USGI Medicals Incisionless Operating Platform to Reduce Pouch Stoma Size in Gastric Bypass Patients 50285 3IU researchers find vibrator use to be common linked to sexual health 50281 1IU researchers find vibrator use to be common linked to sexual health 50281 2IU researchers find vibrator use to be common linked to sexual health 50281 3